Fortis Healthcare Ltd
Fortis Healthcare Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Hospital revenue expected to grow with addition of ~900 beds in FY26; about 50% to be operationalized within the year. Hospital business: Expecting 2% margin improvement over the year; strong first quarter and new brownfield capacity expansions could support this (Page 7, 16). - Diagnostics business: Margin guidance around 22%-23% for the full year; growth projected at high single digits (around 9%-10%) in next few quarters moving towards low double digits in 6-8 quarters (Pages 7, 16). - Revenue growth: Hospital revenues grew 18.6% YoY; Diagnostics net revenue grew 6.3% YoY with improving operating EBITDA (Page 3). - ARPOB growth in hospital business expected around 5%-6%, supported by increasing share of complex cases and robotic surgeries growing at 50%-75% YoY (Pages 4, 13, 14). - Addition of approx.
From Fortis Healthcare Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Hospital revenue expected to grow with addition of ~900 beds in FY26; about 50% to be operationalized within the year.
- Ramp-up of Manesar facility anticipated to reach EBITDA breakeven soon with increasing monthly revenue.
- ARPOB (Average Revenue Per Occupied Bed) growth projected around 5-6%, driven by day care, OPD, and robotic surgeries.
- Oncology revenue growing at ~27-28% CAGR; contribution currently about 17-20% of total hospital revenue.
- Robotic surgeries showing 75% YoY growth; expected to grow at ~50% next year with addition of new robotic machines.
- Diagnostics gross revenue grew 7.4% YoY; operating EBITDA margins expected around 22-23% for the year.
- Diagnostics volume growth ~5% with revenue growth moving from high single-digit towards early double-digit within 6-8 quarters.
2 more points from Fortis Healthcare Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Fortis Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fortis Healthcare currently has approximately 15 robotic machines across its network and plans to add 4 more this year.
- Each da Vinci robotic machine costs around INR 12 crores, while orthopedic robots cost about INR 5 crores.
- The company is investing in oncology setups, adding oncology services to hospitals where it is currently not available, expecting continued oncology growth of about 27-28% CAGR.
- Brownfield expansions include adding about 450 beds in Mohali, 250 beds in Jalandhar, and 180 beds in Amritsar.
- A new 200-bed facility is planned for Manesar, and capacity additions are planned at Noida (including a 60-bed addition), Faridabad, and other locations.
2 more points from Fortis Healthcare Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fortis Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Fortis Healthcare Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Fortis Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.4K Cr, net profit ₹271 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fortis Health.'s management said in earlier quarters
Others in Healthcare Services this season
- Aster DM Quality Care Ltd (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
- Dr Agarwals Health Care Ltd (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
- Syngene Intl. (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
- Yatharth Hospital & Trauma Care Services Ltd (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…
Arthneeti Pro · Annual
Fortis Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fortis Healthcare Ltd Q1 FY26 results?
Hospital revenue expected to grow with addition of ~900 beds in FY26; about 50% to be operationalized within the year. Hospital business: Expecting 2% margin improvement over the year; strong first quarter and new brownfield capacity expansions could support this (Page 7, 16). - Diagnostics business: Margin guidance around 22%-23% for the full year; growth projected at high single digits (around 9%-10%) in next few quarters moving towards low double digits in 6-8 quarters (Pages 7, 16). - Revenue growth: Hospital revenues grew 18.6% YoY; Diagnostics net revenue grew 6.3% YoY with improving operating EBITDA (Page 3). - ARPOB growth in hospital business expected around 5%-6%, supported by increasing share of complex cases and robotic surgeries growing at 50%-75% YoY (Pages 4, 13, 14). - Addition of approx.
What is Fortis Healthcare Ltd share price analysis?
Fortis Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 66.1 with a market cap of ₹69,834 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fortis Healthcare Ltd planning capital expenditure?
Fortis Healthcare currently has approximately 15 robotic machines across its network and plans to add 4 more this year.
Keep Fortis Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.